{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T12:42:36Z","timestamp":1794487356648,"version":"4.9.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"8100","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2026,2,5]]},"DOI":"10.1038\/s41586-025-09828-9","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T16:01:32Z","timestamp":1765382492000},"page":"242-250","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Agonists for cytosolic bacterial receptor ALPK1 induce antitumour immunity"],"prefix":"10.1038","volume":"650","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1698-6065","authenticated-orcid":false,"given":"Xiaoying","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2287-5400","authenticated-orcid":false,"given":"Jiaqi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yupeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4787-4644","authenticated-orcid":false,"given":"Yuanhanyu","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huabin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"She","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9941-7997","authenticated-orcid":false,"given":"Jingjin","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8517-6480","authenticated-orcid":false,"given":"Ping","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4529-5570","authenticated-orcid":false,"given":"Chao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9562-7791","authenticated-orcid":false,"given":"Feng","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"9828_CR1","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1158\/2159-8290.CD-18-0280","volume":"8","author":"A Ribas","year":"2018","unstructured":"Ribas, A. et al. SD-101 in combination with pembrolizumab in advanced melanoma: results of a phase Ib, multicenter study. Cancer Discov. 8, 1250\u20131257 (2018).","journal-title":"Cancer Discov."},{"key":"9828_CR2","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s43018-020-00136-x","volume":"2","author":"SE Ackerman","year":"2021","unstructured":"Ackerman, S. E. et al. Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity. Nat. Cancer 2, 18\u201333 (2021).","journal-title":"Nat. Cancer"},{"key":"9828_CR3","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/s41586-018-0705-y","volume":"564","author":"JM Ramanjulu","year":"2018","unstructured":"Ramanjulu, J. M. et al. Design of amidobenzimidazole STING receptor agonists with systemic activity. Nature 564, 439\u2013443 (2018).","journal-title":"Nature"},{"key":"9828_CR4","unstructured":"Pan, B. S. et al. An orally available non-nucleotide STING agonist with antitumor activity. Science 369, eaba6098 (2020)."},{"key":"9828_CR5","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/s41586-018-0433-3","volume":"561","author":"P Zhou","year":"2018","unstructured":"Zhou, P. et al. Alpha-kinase 1 is a cytosolic innate immune receptor for bacterial ADP-heptose. Nature 561, 122\u2013126 (2018).","journal-title":"Nature"},{"key":"9828_CR6","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1016\/j.celrep.2017.08.039","volume":"20","author":"S Zimmermann","year":"2017","unstructured":"Zimmermann, S. et al. ALPK1- and TIFA-dependent innate immune response triggered by the Helicobacter pylori type IV secretion system. Cell Rep. 20, 2384\u20132395 (2017).","journal-title":"Cell Rep."},{"key":"9828_CR7","doi-asserted-by":"publisher","first-page":"e1006224","DOI":"10.1371\/journal.ppat.1006224","volume":"13","author":"M Milivojevic","year":"2017","unstructured":"Milivojevic, M. et al. ALPK1 controls TIFA\/TRAF6-dependent innate immunity against heptose-1,7-bisphosphate of gram-negative bacteria. PLoS Pathog. 13, e1006224 (2017).","journal-title":"PLoS Pathog."},{"key":"9828_CR8","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1038\/s41436-019-0476-3","volume":"21","author":"LB Williams","year":"2019","unstructured":"Williams, L. B. et al. ALPK1 missense pathogenic variant in five families leads to ROSAH syndrome, an ocular multisystem autosomal dominant disorder. Genet. Med. 21, 2103\u20132115 (2019).","journal-title":"Genet. Med."},{"key":"9828_CR9","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1084\/jem.20120239","volume":"209","author":"O Boulard","year":"2012","unstructured":"Boulard, O., Kirchberger, S., Royston, D. J., Maloy, K. J. & Powrie, F. M. Identification of a genetic locus controlling bacteria-driven colitis and associated cancer through effects on innate inflammation. J. Exp. Med. 209, 1309\u20131324 (2012).","journal-title":"J. Exp. Med."},{"key":"9828_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06085-5","volume":"9","author":"G Ryzhakov","year":"2018","unstructured":"Ryzhakov, G. et al. Alpha kinase 1 controls intestinal inflammation by suppressing the IL-12\/Th1 axis. Nat. Commun. 9, 3797 (2018).","journal-title":"Nat. Commun."},{"key":"9828_CR11","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1152\/physiolgenomics.00084.2013","volume":"45","author":"M Buettner","year":"2013","unstructured":"Buettner, M. & Bleich, A. Mapping colitis susceptibility in mouse models: distal chromosome 3 contains major loci related to Cdcs1. Physiol. Genom. 45, 925\u2013930 (2013).","journal-title":"Physiol. Genom."},{"key":"9828_CR12","doi-asserted-by":"publisher","first-page":"7137","DOI":"10.1073\/pnas.1104234108","volume":"108","author":"J Ermann","year":"2011","unstructured":"Ermann, J. et al. Severity of innate immune-mediated colitis is controlled by the cytokine deficiency-induced colitis susceptibility-1 (Cdcs1) locus. Proc. Natl Acad. Sci. USA 108, 7137\u20137141 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"9828_CR13","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/cr.2016.149","volume":"27","author":"L Corrales","year":"2017","unstructured":"Corrales, L., Matson, V., Flood, B., Spranger, S. & Gajewski, T. F. Innate immune signaling and regulation in cancer immunotherapy. Cell Res. 27, 96\u2013108 (2017).","journal-title":"Cell Res."},{"key":"9828_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41586-019-1593-5","volume":"574","author":"O Demaria","year":"2019","unstructured":"Demaria, O. et al. Harnessing innate immunity in cancer therapy. Nature 574, 45\u201356 (2019).","journal-title":"Nature"},{"key":"9828_CR15","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1126\/science.adk7314","volume":"385","author":"Y Tang","year":"2024","unstructured":"Tang, Y. et al. The beta-d-manno-heptoses are immune agonists across kingdoms. Science 385, 678\u2013684 (2024).","journal-title":"Science"},{"key":"9828_CR16","doi-asserted-by":"publisher","first-page":"e1009787","DOI":"10.1371\/journal.ppat.1009787","volume":"17","author":"J Cui","year":"2021","unstructured":"Cui, J. et al. The ALPK1 pathway drives the inflammatory response to Campylobacter jejuni in human intestinal epithelial cells. PLoS Pathog. 17, e1009787 (2021).","journal-title":"PLoS Pathog."},{"key":"9828_CR17","doi-asserted-by":"publisher","first-page":"102301","DOI":"10.1016\/j.coi.2023.102301","volume":"82","author":"L Faass","year":"2023","unstructured":"Faass, L., Hauke, M., Stein, S. C. & Josenhans, C. Innate immune activation and modulatory factors of Helicobacter pylori towards phagocytic and nonphagocytic cells. Curr. Opin. Immunol. 82, 102301 (2023).","journal-title":"Curr. Opin. Immunol."},{"key":"9828_CR18","doi-asserted-by":"publisher","first-page":"9087","DOI":"10.1096\/fj.201802555R","volume":"33","author":"L Pfannkuch","year":"2019","unstructured":"Pfannkuch, L. et al. ADP heptose, a novel pathogen-associated molecular pattern identified in Helicobacter pylori. FASEB J. 33, 9087\u20139099 (2019).","journal-title":"FASEB J."},{"key":"9828_CR19","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2022.2110639","volume":"14","author":"C Martin-Gallausiaux","year":"2022","unstructured":"Martin-Gallausiaux, C. et al. Akkermansia muciniphila upregulates genes involved in maintaining the intestinal barrier function via ADP-heptose-dependent activation of the ALPK1\/TIFA pathway. Gut Microbes 14, 2110639 (2022).","journal-title":"Gut Microbes"},{"key":"9828_CR20","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2023.2295384","volume":"16","author":"C Martin-Gallausiaux","year":"2024","unstructured":"Martin-Gallausiaux, C. et al. Fusobacterium nucleatum promotes inflammatory and anti-apoptotic responses in colorectal cancer cells via ADP-heptose release and ALPK1\/TIFA axis activation. Gut Microbes 16, 2295384 (2024).","journal-title":"Gut Microbes"},{"key":"9828_CR21","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1136\/annrheumdis-2022-222629","volume":"81","author":"CT Kozycki","year":"2022","unstructured":"Kozycki, C. T. et al. Gain-of-function mutations in ALPK1 cause an NF-\u03baB-mediated autoinflammatory disease: functional assessment, clinical phenotyping and disease course of patients with ROSAH syndrome. Ann. Rheum. Dis. 81, 1453\u20131464 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"9828_CR22","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s10875-021-01087-3","volume":"41","author":"Y Jamilloux","year":"2021","unstructured":"Jamilloux, Y. et al. ALPK1 gene mutations drive autoinflammation with ectodermal dysplasia and progressive vision loss. J. Clin. Immunol. 41, 1671\u20131673 (2021).","journal-title":"J. Clin. Immunol."},{"key":"9828_CR23","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s10875-020-00741-6","volume":"40","author":"L Zhong","year":"2020","unstructured":"Zhong, L. et al. Juvenile onset splenomegaly and oculopathy due to germline mutation in ALPK1. J. Clin. Immunol. 40, 350\u2013358 (2020).","journal-title":"J. Clin. Immunol."},{"key":"9828_CR24","doi-asserted-by":"crossref","unstructured":"Sun, Z. et al. Ocular manifestations of ROSAH syndrome caused by different mutations of the ALPK1 gene. Am. J. Ophthalmol. 281, 456\u2013464 (2025).","DOI":"10.1016\/j.ajo.2025.09.049"},{"key":"9828_CR25","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1038\/s41431-019-0421-6","volume":"27","author":"E Sangiorgi","year":"2019","unstructured":"Sangiorgi, E. et al. Rare missense variants in the ALPK1 gene may predispose to periodic fever, aphthous stomatitis, pharyngitis and adenitis (PFAPA) syndrome. Eur. J. Hum. Genet. 27, 1361\u20131368 (2019).","journal-title":"Eur. J. Hum. Genet."},{"key":"9828_CR26","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1084\/jem.178.3.1057","volume":"178","author":"AD Luster","year":"1993","unstructured":"Luster, A. D. & Leder, P. IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo. J. Exp. Med. 178, 1057\u20131065 (1993).","journal-title":"J. Exp. Med."},{"key":"9828_CR27","doi-asserted-by":"publisher","first-page":"6944","DOI":"10.4049\/jimmunol.166.11.6944","volume":"166","author":"U Pertl","year":"2001","unstructured":"Pertl, U. et al. IFN-\u03b3-inducible protein-10 is essential for the generation of a protective tumor-specific CD8 T cell response induced by single-chain IL-12 gene therapy. J. Immunol. 166, 6944\u20136951 (2001).","journal-title":"J. Immunol."},{"key":"9828_CR28","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.4049\/jimmunol.168.7.3195","volume":"168","author":"JH Dufour","year":"2002","unstructured":"Dufour, J. H. et al. IFN-\u03b3-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J. Immunol. 168, 3195\u20133204 (2002).","journal-title":"J. Immunol."},{"key":"9828_CR29","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.ajpath.2011.09.005","volume":"180","author":"Y Nakasone","year":"2012","unstructured":"Nakasone, Y. et al. Host-derived MCP-1 and MIP-1alpha regulate protective anti-tumor immunity to localized and metastatic B16 melanoma. Am. J. Pathol. 180, 365\u2013374 (2012).","journal-title":"Am. J. Pathol."},{"key":"9828_CR30","doi-asserted-by":"publisher","first-page":"6673","DOI":"10.4049\/jimmunol.1300434","volume":"190","author":"T Lanca","year":"2013","unstructured":"Lanca, T. et al. Protective role of the inflammatory CCR2\/CCL2 chemokine pathway through recruitment of type 1 cytotoxic gammadelta T lymphocytes to tumor beds. J. Immunol. 190, 6673\u20136680 (2013).","journal-title":"J. Immunol."},{"key":"9828_CR31","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1089\/jir.2008.0027","volume":"29","author":"SL Deshmane","year":"2009","unstructured":"Deshmane, S. L., Kremlev, S., Amini, S. & Sawaya, B. E. Monocyte chemoattractant protein-1 (MCP-1): an overview. J. Interferon Cytokine Res. 29, 313\u2013326 (2009).","journal-title":"J. Interferon Cytokine Res."},{"key":"9828_CR32","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1126\/science.1164206","volume":"322","author":"K Hildner","year":"2008","unstructured":"Hildner, K. et al. Batf3 deficiency reveals a critical role for CD8\u03b1+ dendritic cells in cytotoxic T cell immunity. Science 322, 1097\u20131100 (2008).","journal-title":"Science"},{"key":"9828_CR33","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1126\/science.ade2292","volume":"381","author":"R Bill","year":"2023","unstructured":"Bill, R. et al. CXCL9: SPP1 macrophage polarity identifies a network of cellular programs that control human cancers. Science 381, 515\u2013524 (2023).","journal-title":"Science"},{"key":"9828_CR34","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1084\/jem.20151193","volume":"213","author":"R Afik","year":"2016","unstructured":"Afik, R. et al. Tumor macrophages are pivotal constructors of tumor collagenous matrix. J. Exp. Med. 213, 2315\u20132331 (2016).","journal-title":"J. Exp. Med."},{"key":"9828_CR35","doi-asserted-by":"publisher","first-page":"5216","DOI":"10.4049\/jimmunol.1300097","volume":"190","author":"J Conlon","year":"2013","unstructured":"Conlon, J. et al. Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid. J. Immunol. 190, 5216\u20135225 (2013).","journal-title":"J. Immunol."},{"key":"9828_CR36","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1158\/1078-0432.CCR-21-1963","volume":"28","author":"F Meric-Bernstam","year":"2022","unstructured":"Meric-Bernstam, F. et al. Phase I dose-escalation trial of MIW815 (ADU-S100), an intratumoral STING agonist, in patients with advanced\/metastatic solid tumors or lymphomas. Clin. Cancer Res. 28, 677\u2013688 (2022).","journal-title":"Clin. Cancer Res."},{"key":"9828_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00573-w","volume":"8","author":"MF Gulen","year":"2017","unstructured":"Gulen, M. F. et al. Signalling strength determines proapoptotic functions of STING. Nat. Commun. 8, 427 (2017).","journal-title":"Nat. Commun."},{"key":"9828_CR38","doi-asserted-by":"publisher","first-page":"397","DOI":"10.4049\/jimmunol.1601999","volume":"199","author":"B Larkin","year":"2017","unstructured":"Larkin, B. et al. Cutting edge: activation of STING in T cells induces type I IFN responses and cell death. J. Immunol. 199, 397\u2013402 (2017).","journal-title":"J. Immunol."},{"key":"9828_CR39","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.1016\/j.cell.2022.09.020","volume":"185","author":"Q Huang","year":"2022","unstructured":"Huang, Q. et al. The primordial differentiation of tumor-specific memory CD8+ T cells as bona fide responders to PD-1\/PD-L1 blockade in draining lymph nodes. Cell 185, 4049\u20134066 (2022).","journal-title":"Cell"},{"key":"9828_CR40","doi-asserted-by":"publisher","first-page":"782852","DOI":"10.3389\/fimmu.2021.782852","volume":"12","author":"GAF Vitiello","year":"2021","unstructured":"Vitiello, G. A. F., Ferreira, W. A. S., Cordeiro de Lima, V. C. & Medina, T. D. S. Antiviral responses in cancer: boosting antitumor immunity through activation of interferon pathway in the tumor microenvironment. Front. Immunol. 12, 782852 (2021).","journal-title":"Front. Immunol."},{"key":"9828_CR41","doi-asserted-by":"publisher","DOI":"10.1126\/science.ade8520","volume":"384","author":"J Zak","year":"2024","unstructured":"Zak, J. et al. JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma. Science 384, eade8520 (2024).","journal-title":"Science"},{"key":"9828_CR42","doi-asserted-by":"publisher","DOI":"10.1126\/science.adf1329","volume":"384","author":"D Mathew","year":"2024","unstructured":"Mathew, D. et al. Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients. Science 384, eadf1329 (2024).","journal-title":"Science"},{"key":"9828_CR43","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","volume":"116","author":"A Morales","year":"1976","unstructured":"Morales, A., Eidinger, D. & Bruce, A. W. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J. Urol. 116, 180\u2013183 (1976).","journal-title":"J. Urol."},{"key":"9828_CR44","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.eururo.2011.03.017","volume":"59","author":"M Babjuk","year":"2011","unstructured":"Babjuk, M. et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur. Urol. 59, 997\u20131008 (2011).","journal-title":"Eur. Urol."},{"key":"9828_CR45","doi-asserted-by":"publisher","first-page":"e2313148120","DOI":"10.1073\/pnas.2313148120","volume":"120","author":"T Snelling","year":"2023","unstructured":"Snelling, T., Saalfrank, A., Wood, N. T. & Cohen, P. ALPK1 mutants causing ROSAH syndrome or Spiradenoma are activated by human nucleotide sugars. Proc. Natl Acad. Sci. USA 120, e2313148120 (2023).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"9828_CR46","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/nature10510","volume":"477","author":"Y Zhao","year":"2011","unstructured":"Zhao, Y. et al. The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus. Nature 477, 596\u2013600 (2011).","journal-title":"Nature"},{"key":"9828_CR47","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1755-1536-3-12","volume":"3","author":"H Wiig","year":"2010","unstructured":"Wiig, H., Tenstad, O., Iversen, P. O., Kalluri, R. & Bjerkvig, R. Interstitial fluid: the overlooked component of the tumor microenvironment? Fibrogenesis Tissue Repair 3, 12 (2010).","journal-title":"Fibrogenesis Tissue Repair"},{"key":"9828_CR48","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1182\/blood-2013-12-545772","volume":"124","author":"CT Mayer","year":"2014","unstructured":"Mayer, C. T. et al. Selective and efficient generation of functional Batf3-dependent CD103+ dendritic cells from mouse bone marrow. Blood 124, 3081\u20133091 (2014).","journal-title":"Blood"}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-09828-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-09828-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-09828-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T01:02:46Z","timestamp":1770253366000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-09828-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":48,"journal-issue":{"issue":"8100","published-print":{"date-parts":[[2026,2,5]]}},"alternative-id":["9828"],"URL":"https:\/\/doi.org\/10.1038\/s41586-025-09828-9","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"assertion":[{"value":"5 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"F.S. is the scientific founder and chair of the scientific advisory board of Pyrotech Therapeutics. This relationship did not influence this study. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}